222,450 Shares in Odyssey Therapeutics, Inc. $ODTX Acquired by Citadel Advisors LLC

Citadel Advisors LLC acquired a new stake in Odyssey Therapeutics, Inc. (NASDAQ:ODTX) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 222,450 shares of the company’s stock, valued at approximately $4,162,000. Citadel Advisors LLC owned approximately 0.46% of Odyssey Therapeutics at the end of the most recent quarter.

Odyssey Therapeutics Stock Performance

Shares of ODTX stock opened at $28.76 on Tuesday. The company has a market cap of $1.38 billion and a P/E ratio of -4.25. Odyssey Therapeutics, Inc. has a 1 year low of $15.10 and a 1 year high of $29.05. The company’s fifty day simple moving average is $20.66.

Odyssey Therapeutics (NASDAQ:ODTX) last announced its earnings results on Wednesday, August 5th. The company reported ($1.74) EPS for the quarter. As a group, sell-side analysts expect that Odyssey Therapeutics, Inc. will post -5.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ODTX has been the topic of a number of research reports. Zacks Research upgraded Odyssey Therapeutics to a “hold” rating in a research note on Wednesday, June 3rd. HC Wainwright started coverage on Odyssey Therapeutics in a research report on Thursday, August 27th. They set a “buy” rating and a $44.00 price objective for the company. Wall Street Zen downgraded Odyssey Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 20th. Weiss Ratings initiated coverage on Odyssey Therapeutics in a research report on Tuesday, August 11th. They issued a “sell (d+)” rating on the stock. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $40.00 price target on shares of Odyssey Therapeutics in a research report on Thursday, June 18th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.75.

Odyssey Therapeutics Profile

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc is based in BOSTON.